TrophiCell

TrophiCell is a private, pre-clinical stage biotech leveraging a foundational discovery by Professor Anthony Hollander to overcome a major limitation in MSC therapeutics. The company's platform identifies a unique MSC population that retains key therapeutic functions like immunomodulation and trophic signaling through extensive in vitro expansion, enabling scalable production from a single source while maintaining a natural MSC safety profile. This positions TrophiCell to develop standardized, optimized cell therapies that could bridge the gap between the safety of natural MSCs and the scalability of iPSC-derived products. The company aims to partner with leading manufacturers and clinical centers to bring these life-enhancing treatments to market.

Proprietary platform identifying and expanding a novel MSC subpopulation defined by high TIMP1 protein and low MMP13 gene expression. This population retains immunomodulatory and trophic repair functions through extensive in vitro expansion, enabling scalable production from a single donor source while maintaining a natural MSC safety profile.

Competes against companies using natural MSCs (e.g., Mesoblast, Pluristem) which face scalability issues, and companies using iPSC-derived MSCs (e.g., Cynata, Heartseed) which face safety and manufacturing complexity. TrophiCell aims to differentiate by offering the safety of natural MSCs with the scalability of an iPSC-like process.